ABBOTT LABORATORIES（ABT）の決算・業績分析
ABBOTT LABORATORIESの2025年有価証券報告書をAI分析。売上高$44.3B(+5.7%)。営業利益$8.1B。Health Care。
目次
ABBOTT LABORATORIESの2025年度 業績サマリー
ABBOTT LABORATORIES（証券コード: ABT）の2025年度決算・業績分析。売上高は$44.3B（前年比+5.7%）。営業利益は$8.1B（前年比+18.0%）。純利益は$6.5B（前年比-51.3%）。有価証券報告書を基に、業績変化の要因・リスク・見通し・セグメント構成を AI が分析しました。
ABBOTT LABORATORIESの2024年度 注目ポイント
※ 直近の2025年度XBRLデータは取込済みですが、AI分析は2024年度の10-Kを対象としています。
- Revenue reached $43.7B in FY2024, reflecting a 1.3% YoY increase (XBRL).
- Operating income declined by 0.7% YoY to $8.4B, while net income fell 2.0% YoY to $6.9B (XBRL).
- Free cash flow (FCF) totaled $7.8B, driven by $9.6B in operating cash flow and $1.8B in capital expenditures (XBRL).
- Net debt stood at $6.7B, or 0.7x EBITDA, indicating a conservative leverage profile (XBRL).
- Net income grew at a 19.3% CAGR over five years, outpacing revenue growth (XBRL).
ABBOTT LABORATORIESの売上高変化の要因
- •Revenue in FY2024 was $43.7B, up 1.3% YoY (XBRL). The 5-year CAGR for revenue is 5.6%, with operating income growing at 12.2% CAGR and net income at 19.3% CAGR (XBRL). The historical time series shows revenue increasing from $30.6B in FY2020 to $43.7B in FY2024, though it declined to $40.1B in FY2025 (XBRL). Growth drivers include expansion in diagnostics and pharmaceuticals, though revenue growth slowed in FY2024 compared to prior years.
ABBOTT LABORATORIESの営業利益変化の要因
- •Profitability metrics in FY2024 include an operating margin of 19.2% and a net margin of 15.9% (XBRL). Operating income declined 0.7% YoY to $8.4B, while EBITDA remained stable at $9.6B (22.0% of revenue) (XBRL). Net income fell 2.0% YoY to $6.9B. The 5-year CAGR for operating income is 12.2%, and net income grew at 19.3% CAGR (XBRL).
ABBOTT LABORATORIESの事業リスクと対応
Supply chain disruptions could harm operations (10-K).
Acquisitions may lead to unanticipated costs or integration challenges (10-K).
Cybersecurity incidents risk data breaches and operational disruptions (10-K).
R&D failures may hinder product success or innovation (10-K).
Data privacy breaches could result in legal penalties and reputational damage (10-K).
Regulatory requirements for data privacy laws may restrict cross-border data transfers (10-K).
ABBOTT LABORATORIESの事業内容
Abbott Laboratories operates as a global healthcare company, generating revenue through the sale of pharmaceuticals, diagnostics, nutritional products, and medical devices (10-K). Its business segments include Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Key customers span government agencies, healthcare facilities, pharmacies, and laboratories, with no significant customer concentration (10-K). The competitive landscape includes other pharmaceutical firms and generic drug substitutes, though no specific competitors are named (10-K).
ABBOTT LABORATORIESのAI業績分析レポート（2024年度）
Abbott Laboratories (ABT) FY2024 Annual Report Analysis
Highlights
Business Overview
Abbott Laboratories operates as a global healthcare company, generating revenue through the sale of pharmaceuticals, diagnostics, nutritional products, and medical devices (10-K). Its business segments include Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Key customers span government agencies, healthcare facilities, pharmacies, and laboratories, with no significant customer concentration (10-K). The competitive landscape includes other pharmaceutical firms and generic drug substitutes, though no specific competitors are named (10-K).
Revenue Analysis
Revenue in FY2024 was $43.7B, up 1.3% YoY (XBRL). The 5-year CAGR for revenue is 5.6%, with operating income growing at 12.2% CAGR and net income at 19.3% CAGR (XBRL). The historical time series shows revenue increasing from $30.6B in FY2020 to $43.7B in FY2024, though it declined to $40.1B in FY2025 (XBRL). Growth drivers include expansion in diagnostics and pharmaceuticals, though revenue growth slowed in FY2024 compared to prior years.
Profitability Analysis
Profitability metrics in FY2024 include an operating margin of 19.2% and a net margin of 15.9% (XBRL). Operating income declined 0.7% YoY to $8.4B, while EBITDA remained stable at $9.6B (22.0% of revenue) (XBRL). Net income fell 2.0% YoY to $6.9B. The 5-year CAGR for operating income is 12.2%, and net income grew at 19.3% CAGR (XBRL).
Balance Sheet Analysis
The company’s equity ratio is 52.7%, with total equity rising to $38.6B in FY2024 (XBRL). Current assets exceed current liabilities, as reflected by a current ratio of 1.64x (XBRL). Total assets declined slightly to $73.2B in FY2024, while long-term debt remained at $13.6B (XBRL). Net debt is $6.7B, or 0.7x EBITDA, indicating a conservative capital structure (XBRL).
Cash Flow Analysis
Operating cash flow totaled $9.6B in FY2024, down from $10.5B in FY2023 (XBRL). Free cash flow was $7.8B, calculated as $9.6B in operating cash flow minus $1.8B in capital expenditures (XBRL). Financing activities included $3.3B in dividends and $3.8B in share repurchases, resulting in a net outflow of $7.6B (XBRL).
Working Capital Analysis
Receivables days were 55 days, and inventory days were 125 days in FY2024 (XBRL). Asset turnover was 0.60x, reflecting moderate efficiency in asset utilization (XBRL). Payables days data is not available, so cash conversion cycle (CCC) cannot be calculated.
Risks
Outlook
N/A
Health Careの企業一覧
ABBOTT LABORATORIESと同じ「Health Care」セクターの企業